Nivolumab and axitnib for renal cell cancer -pro
While there are ongoing trials of axitnib alone or with novel agents, the combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.
NCCN, Kidney Cancer 2023
Matthew R. Zibelman, Michael Anthony Carducci, Yasser Ged, Ana M. Molina, Rahul Ravilla, David R. Shafferet al, A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma. Journal of Clinical Oncology Volume 40, Issue 6_suppl > Meeting Abstract | 2022 ASCO Genitourinary Cancers Symposium RENAL CELL CANCER